Cardiovascular disease and risk in COPD: a state of the art review

References

• Alvar Agusti MC, Richard Beasley M, Bartolome R, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023.
   Google Scholar
• Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. doi: 10.1183/13993003.01499-2021
   PubMed Web of Science ®Google Scholar
• van der Velden RMJ, Hermans ANL, Pluymaekers NAHA, et al. Dyspnea in patients with atrial fibrillation: mechanisms, assessment and an interdisciplinary and integrated care approach. Int J Cardiol Heart Vasc. 2022;42:101086. doi: 10.1016/j.ijcha.2022.101086
   PubMed Web of Science ®Google Scholar
• Ananth S, Hurst JR. ERJ advances: state of the art in definitions and diagnosis of COPD. Eur Respir J. 2023;61(4):2202318. doi: 10.1183/13993003.02318-2022
   PubMed Web of Science ®Google Scholar
• Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 2019;7(4):358–364. doi: 10.1016/S2213-2600(18)30529-0
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Celli BR, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med. 2021;203(4):414–423. doi: 10.1164/rccm.202008-3328PP
   PubMed Web of Science ®Google Scholar
• Higbee DH, Granell R, Davey Smith G, et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK biobank cohort analysis. Lancet Respir Med. 2022;10(2):149–157. doi: 10.1016/S2213-2600(21)00369-6
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057. doi: 10.1183/16000617.0057-2018
   PubMed Web of Science ®Google Scholar
• Labaki WW, Gu T, Murray S, et al. Causes of and clinical features associated with death in tobacco cigarette users by lung function impairment. Am J Respir Crit Care Med. 2023;208(4):451–460. doi: 10.1164/rccm.202210-1887OC
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi: 10.1183/13993003.00239-2023
   PubMed Web of Science ®Google Scholar
• Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458. doi: 10.1016/S2213-2600(21)00511-7
   PubMed Web of Science ®Google Scholar
• Siddharthan T, Pollard SL, Quaderi SA, et al. Discriminative accuracy of chronic obstructive pulmonary disease screening instruments in 3 low- and middle-income country settings. JAMA. 2022;327(2):151–160. doi: 10.1001/jama.2021.23065
   PubMed Web of Science ®Google Scholar
• Sievi NA, Sepin J, Roeder M, et al. Are predictors for overall Mortality in COPD patients robust over Time? J Clin Med. 2023;12(4):1587. doi: 10.3390/jcm12041587
   PubMed Web of Science ®Google Scholar
• Chen S, Kuhn M, Prettner K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. Lancet Glob Health. 2023;11(8):e1183–e1193.
   PubMed Web of Science ®Google Scholar
• Tabyshova A, Hurst JR, Soriano JB, et al. Gaps in COPD guidelines of low- and middle-income countries: a systematic scoping review. Chest. 2021;159(2):575–584. doi: 10.1016/j.chest.2020.09.260
   PubMed Web of Science ®Google Scholar
• Hurst JR, Buist AS, Gaga M, et al. Challenges in the Implementation of chronic obstructive pulmonary disease Guidelines in low- and middle-income countries: an official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2021;18(8):1269–1277. doi: 10.1513/AnnalsATS.202103-284ST
   PubMed Web of Science ®Google Scholar
• Florman KEH, Siddharthan T, Pollard SL, et al. Unmet diagnostic and therapeutic opportunities for chronic obstructive pulmonary disease in low- and middle-income countries. Am J Respir Crit Care Med. 2023;208(4):442–450. doi: 10.1164/rccm.202302-0289OC
   PubMed Web of Science ®Google Scholar
• Agarwal D. COPD generates substantial cost for health systems. Lancet Glob Health. 2023;11(8):e1138–e1139. doi: 10.1016/S2214-109X(23)00304-2
   PubMed Web of Science ®Google Scholar
• Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol. 2017;70(2):128–134. doi: 10.1016/j.jjcc.2017.03.001
   PubMed Web of Science ®Google Scholar
• Maclagan LC, Croxford R, Chu A, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J. 2023;62(2):2202364. doi: 10.1183/13993003.02364-2022
   PubMed Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi: 10.1016/S2213-2600(15)00241-6
   PubMed Web of Science ®Google Scholar
• Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524. doi: 10.1177/1753465817750524
   Web of Science ®Google Scholar
• Kibbler J, Wade C, Mussell G, et al. Systematic review and meta-analysis of prevalence of undiagnosed major cardiac comorbidities in COPD. ERJ Open Res. 2023;9(6):00548–02023. Published online October 12. doi: 10.1183/23120541.00548-2023.
   PubMedGoogle Scholar
• Goedemans L, Bax JJ, Delgado V. COPD and acute myocardial infarction. Eur Respir Rev. 2020;29(156):190139. doi: 10.1183/16000617.0139-2019
   PubMed Web of Science ®Google Scholar
• Campo G, Pavasini R, Malagù M, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015;29(2):147–157. doi: 10.1007/s10557-014-6569-y
   PubMed Web of Science ®Google Scholar
• Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi: 10.1164/rccm.201201-0034OC
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG, et al. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir med. 2015;109(8):1019–1025. doi: 10.1016/j.rmed.2015.05.021
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Nath HP, Kim YI, et al. Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort. Respir Res. 2018;19(1):257. doi: 10.1186/s12931-018-0946-1
   PubMedGoogle Scholar
• Chandra D, Gupta A, Kinney GL, et al. The association between lung hyperinflation and coronary artery disease in smokers. Chest. 2021;160(3):858–871. doi: 10.1016/j.chest.2021.04.066
   PubMed Web of Science ®Google Scholar
• Papaporfyriou A, Bartziokas K, Gompelmann D, et al. Cardiovascular diseases in COPD: from diagnosis and prevalence to therapy. Life (Basel). 2023;13(6):1299. doi: 10.3390/life13061299
   PubMed Web of Science ®Google Scholar
• Mooney L, Hawkins NM, Jhund PS, et al. Impact of chronic obstructive pulmonary disease in patients with Heart failure with preserved ejection fraction: insights from PARAGON-HF. J Am Heart Assoc. 2021;10(23):e021494. doi: 10.1161/JAHA.121.021494
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Peterson S, Salimian S, et al. Epidemiology and treatment of heart failure with chronic obstructive pulmonary disease in Canadian primary care. ESC Heart Fail. 2023;10(6):3612–3621.
   PubMed Web of Science ®Google Scholar
• Axson EL, Ragutheeswaran K, Sundaram V, et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res. 2020;21(1):54. doi: 10.1186/s12931-020-1312-7
   PubMed Web of Science ®Google Scholar
• Ehteshami-Afshar S, Mooney L, Dewan P, et al. Clinical characteristics and outcomes of patients with Heart failure with Reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. J Am Heart Assoc. 2021;10(4):e019238. doi: 10.1161/JAHA.120.019238
   PubMed Web of Science ®Google Scholar
• Canepa M, Franssen FME, Olschewski H, et al. Diagnostic and therapeutic gaps in patients with Heart failure and chronic obstructive pulmonary disease. JACC Heart Fail. 2019;7(10):823–833. doi: 10.1016/j.jchf.2019.05.009
   PubMed Web of Science ®Google Scholar
• Rutten FH, Cramer MJM, Lammers JWJ, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8(7):706–711. doi: 10.1016/j.ejheart.2006.01.010
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–139. doi: 10.1093/eurjhf/hfn013
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu Y, Zhao S, et al. The incidence and prevalence of pulmonary hypertension in the COPD population: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2022;17:1365–1379. doi: 10.2147/COPD.S359873
   PubMed Web of Science ®Google Scholar
• Blanco I, Tura-Ceide O, Peinado V VI. Updated perspectives on pulmonary hypertension in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1315–1324. doi:10.2147/COPD.S211841.
   PubMed Web of Science ®Google Scholar
• Olsson KM, Corte TJ, Kamp JC, et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management. Lancet Respir Med. 2023;11(9):820–835. doi: 10.1016/S2213-2600(23)00259-X
   PubMed Web of Science ®Google Scholar
• Barnes H, Brown Z, Burns A, et al. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019;2019(3):CD012621. doi: 10.1002/14651858.CD012621.pub2
   Google Scholar
• Simons SO, Elliott A, Sastry M, et al. Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. Eur Heart J. 2021;42(5):532–540. doi: 10.1093/eurheartj/ehaa822
   PubMed Web of Science ®Google Scholar
• Proietti M, Laroche C, Drozd M, et al. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Am Heart J. 2016;181:83–91. doi: 10.1016/j.ahj.2016.08.011
   PubMed Web of Science ®Google Scholar
• Durheim MT, Holmes DN, Blanco RG, et al. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018;104(22):1850–1858. doi: 10.1136/heartjnl-2017-312735
   PubMed Web of Science ®Google Scholar
• Emil Warming P, Garcia R, Johann Hansen C, et al. Atrial fibrillation and chronic obstructive pulmonary disease: diagnostic sequence and mortality risk. Eur Heart J Qual Care Clin Outcomes. 2023;9(2): 128–134. doi: 10.1093/ehjqcco/qcac059
   PubMed Web of Science ®Google Scholar
• Warming PE, Garcia GR, Hansen CJ, et al. Atrial fibrillation and chronic obstructive pulmonary disease: diagnostic sequence and mortality risk. Eur Heart J Qual Care Clin Outcomes. Published online Feb 2023;9(2):128–134. doi: 10.1093/ehjqcco/qcac059
   PubMed Web of Science ®Google Scholar
• Shah AJ, Quek E, Alqahtani JS, et al. Cardiovascular outcomes in patients with COPD-OSA overlap syndrome: A systematic review and meta-analysis. Sleep Med Rev. 2022;63:101627. doi: 10.1016/j.smrv.2022.101627
   PubMed Web of Science ®Google Scholar
• Gleeson M, McNicholas WT. Bidirectional relationships of comorbidity with obstructive sleep apnoea. Eur Respir Rev. 2022;31(164):210256. doi: 10.1183/16000617.0256-2021
   PubMed Web of Science ®Google Scholar
• Bouloukaki I, Fanaridis M, Testelmans D, et al. Overlaps between obstructive sleep apnoea and other respiratory diseases, including COPD, asthma and interstitial lung disease. Breathe. 2022;18(3):220073. doi: 10.1183/20734735.0073-2022
   Web of Science ®Google Scholar
• Messineo L, Lonni S, Magri R, et al. Lung air trapping lowers respiratory arousal threshold and contributes to sleep apnea pathogenesis in COPD patients with overlap syndrome. Respir Physiol Neurobiol. 2020;271:103315. doi: 10.1016/j.resp.2019.103315
   PubMed Web of Science ®Google Scholar
• McNicholas WT. COPD-OSA Overlap Syndrome: Evolving Evidence Regarding Epidemiology, Clinical Consequences, and Management. Chest. 2017;152(6):1318–1326. doi: 10.1016/j.chest.2017.04.160
   PubMed Web of Science ®Google Scholar
• Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–633. doi: 10.1378/chest.10-2948
   PubMed Web of Science ®Google Scholar
• Shawon MSR, Perret JL, Senaratna CV, et al. Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease: A systematic review. Sleep Med Rev. 2017;32:58–68. doi: 10.1016/j.smrv.2016.02.007
   PubMed Web of Science ®Google Scholar
• McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnoea-the overlap syndrome. J Thorac Dis. 2016;8(2):236–242. doi: 10.21037/jtd.2016.12.36
   PubMed Web of Science ®Google Scholar
• van Zeller M, Basoglu OK, Verbraecken J, et al. Sleep and cardiometabolic comorbidities in the obstructive sleep apnoea-COPD overlap syndrome: data from the European Sleep Apnoea Database. ERJ Open Res. 2023;9(3). doi: 10.1183/23120541.00676-2022
   Google Scholar
• Sodhi A, Pisani M, Glassberg MK, et al. Sex and Gender in Lung Disease and Sleep Disorders: A State-of-the-Art Review. Chest. 2022;162(3):647–658. doi: 10.1016/j.chest.2022.03.006
   PubMed Web of Science ®Google Scholar
• Sánchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, et al. Adherence to CPAP Treatment and the risk of recurrent cardiovascular events: a meta-analysis. JAMA. 2023;330(13):1255–1265. doi: 10.1001/jama.2023.17465
   PubMed Web of Science ®Google Scholar
• Macrea M, Oczkowski S, Rochwerg B, et al. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease. an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(4):e74–e87. doi: 10.1164/rccm.202006-2382ST
   PubMed Web of Science ®Google Scholar
• Almagro P, Boixeda R, Diez-Manglano J, et al. Insights into chronic obstructive pulmonary disease as critical risk factor for cardiovascular disease. Int J Chron Obstruct Pulmon Dis. 2020;15:755–764. doi:10.2147/COPD.S238214.
   PubMed Web of Science ®Google Scholar
• Gallucci G, Tartarone A, Lerose R, et al. Cardiovascular risk of smoking and benefits of smoking cessation. J Thorac Dis. 2020;12(7):3866–3876. doi: 10.21037/jtd.2020.02.47
   PubMed Web of Science ®Google Scholar
• Kotlyarov S. The role of smoking in the mechanisms of development of chronic obstructive pulmonary disease and atherosclerosis. Int J Mol Sci. 2023;24(10):8725. doi: 10.3390/ijms24108725
   PubMed Web of Science ®Google Scholar
• Doo JH, Kim SM, Park YJ, et al. Smoking cessation after diagnosis of COPD is associated with lower all-cause and cause-specific mortality: a nationwide population-based cohort study of South Korean men. BMC Pulm Med. 2023;23(1):237. doi: 10.1186/s12890-023-02533-1
   PubMed Web of Science ®Google Scholar
• MacNee W. Is chronic obstructive pulmonary disease an accelerated aging disease? Ann Am Thorac Soc. 2016;13(Suppl 5):S429–S437. doi: 10.1513/AnnalsATS.201602-124AW
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Senescence in COPD and its comorbidities. Annu Rev Physiol. 2017;79(1):517–539. doi: 10.1146/annurev-physiol-022516-034314
   PubMed Web of Science ®Google Scholar
• North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097–1108. doi: 10.1161/CIRCRESAHA.111.246876
   PubMed Web of Science ®Google Scholar
• Agustí A, Noell G, Brugada J, et al. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5(12):935–945. doi: 10.1016/S2213-2600(17)30434-4
   PubMed Web of Science ®Google Scholar
• Gredic M, Blanco I, Kovacs G, et al. Pulmonary hypertension in chronic obstructive pulmonary disease. Br J Pharmacol. 2021;178(1):132–151. doi: 10.1111/bph.14979
   PubMed Web of Science ®Google Scholar
• Jörgensen K, Müller MF, Nel J, et al. Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest. 2007;131(4):1050–1057. doi: 10.1378/chest.06-2245
   PubMed Web of Science ®Google Scholar
• van der Molen MC, Hartman JE, Vanfleteren LEGW, et al. Reduction of Lung Hyperinflation Improves Cardiac Preload, Contractility, and Output in Emphysema: A Clinical Trial in Patients Who Received Endobronchial Valves. Am J Respir Crit Care Med. 2022;206(6):704–711. doi: 10.1164/rccm.202201-0214OC
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–378. doi: 10.1016/S2213-2600(18)30054-7
   PubMed Web of Science ®Google Scholar
• Smith BM, Kawut SM, Bluemke DA, et al. Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. Circulation. 2013;127(14):1503–1511, 1511e1–6. doi: 10.1161/CIRCULATIONAHA.113.001653
   Web of Science ®Google Scholar
• Short PM, Anderson WJ, Elder DHJ, et al. Impact of left ventricular hypertrophy on survival in chronic obstructive pulmonary disease. Lung. 2015;193(4):487–495. doi: 10.1007/s00408-015-9724-8
   PubMed Web of Science ®Google Scholar
• Smith JR, Johnson BD, Olson TP. Impaired central hemodynamics in chronic obstructive pulmonary disease during submaximal exercise. J Appl Physiol (1985). 2019;127(3):691–697. doi: 10.1152/japplphysiol.00877.2018
   PubMed Web of Science ®Google Scholar
• Sacramento-Pacheco J, Duarte-Clíments G, Gómez-Salgado J, et al. Cardiovascular risk assessment tools: A scoping review. Aust Crit Care. 2019;32(6):540–559. doi: 10.1016/j.aucc.2018.09.008
   PubMed Web of Science ®Google Scholar
• Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Of Systematic Reviews. 2017;2021(6):CD006887. doi: 10.1002/14651858.CD006887.pub4
   Google Scholar
• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. doi: 10.1136/bmj.j2099
   PubMed Web of Science ®Google Scholar
• van Staa TP, Gulliford M, Ng ES-W, et al. Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk? PLoS One. 2014;9(10):e106455. doi: 10.1371/journal.pone.0106455
   PubMed Web of Science ®Google Scholar
• Balbirsingh V, Mohammed AS, Turner AM, et al. Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review. Thorax. Published online Jun 30, 2022;77(9):939–945. doi: 10.1136/thoraxjnl-2021-218333
   Web of Science ®Google Scholar
• Young KA, Regan EA, Han MK, et al. Subtypes of COPD have unique distributions and differential risk of mortality. Chronic Obstr Pulm Dis. 2019;6(5):400–413. doi: 10.15326/jcopdf.6.5.2019.0150
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi: 10.1093/eurheartj/ehz425
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Van Gelder IC, Desteghe L, et al. ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: the Horizon 2020 EHRA-PATHS project. European Heart Journal. 2022;43(15):1450–1452. doi: 10.1093/eurheartj/ehab672
   PubMed Web of Science ®Google Scholar
• Lee G, Baker E, Collins R, et al. The challenge of managing multimorbid atrial fibrillation: a pan-European European Heart Rhythm Association (EHRA) member survey of current management practices and clinical priorities. EP Europace. 2022;24(12):2004–2014. doi: 10.1093/europace/euac136
   PubMed Web of Science ®Google Scholar
• Zhou J, Li X, Wang X, et al. Accuracy of portable spirometers in the diagnosis of chronic obstructive pulmonary disease a meta-analysis. NPJ Prim Care Respir Med. 2022;32(1):15. doi: 10.1038/s41533-022-00275-x
   PubMed Web of Science ®Google Scholar
• Ioannides AE, Tayal U, Quint JK. Spirometry in atrial fibrillation: What’s the catch? Expert Rev Respir Med. Published online Nov 8, 2023;17(10):937–950. doi: 10.1080/17476348.2023.2279236
   PubMed Web of Science ®Google Scholar
• Chase SC, Fermoyle CC, Wheatley CM, et al. The effect of diuresis on extravascular lung water and pulmonary function in acute decompensated heart failure. ESC Heart Fail. 2018;5(2):364–371. doi: 10.1002/ehf2.12253
   PubMed Web of Science ®Google Scholar
• Iversen KK, Kjaergaard J, Akkan D, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264(4):361–369. doi: 10.1111/j.1365-2796.2008.01975.x
   PubMed Web of Science ®Google Scholar
• Güder G, Brenner S, Störk S, et al. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail. 2014;16(12):1273–1282. doi: 10.1002/ejhf.183
   PubMed Web of Science ®Google Scholar
• Magnussen H, Canepa M, Zambito PE, et al. What can we learn from pulmonary function testing in heart failure? Eur J Heart Fail. 2017;19(10):1222–1229. doi: 10.1002/ejhf.946
   PubMed Web of Science ®Google Scholar
• Contini M, Conte E, Agostoni P. Lung function evaluation in heart failure: possible pitfalls. Breathe. 2020;16(1):190316. doi: 10.1183/20734735.0316-2019
   Web of Science ®Google Scholar
• Roversi S, Fabbri LM, Sin DD, et al. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for Integrated Care. Am J Respir Crit Care Med. 2016;194(11):1319–1336. doi: 10.1164/rccm.201604-0690SO
   PubMed Web of Science ®Google Scholar
• Smith JR, Van Iterson EH, Johnson BD, et al. Exercise ventilatory inefficiency in heart failure and chronic obstructive pulmonary disease. Int J Cardiol. 2019;274:232–236. doi: 10.1016/j.ijcard.2018.09.007
   PubMed Web of Science ®Google Scholar
• Au Yeung SL, Borges MC, Lawlor DA, et al. Impact of lung function on cardiovascular diseases and cardiovascular risk factors: a two sample bidirectional Mendelian randomisation study. Thorax. 2022;77(2):164–171. doi: 10.1136/thoraxjnl-2020-215600
   PubMed Web of Science ®Google Scholar
• Ramalho SHR, Claggett BL, Washko GR, et al. Association of pulmonary function with late-life cardiac function and Heart failure risk: the ARIC study. J Am Heart Assoc. 2022;11(14):e023990. doi: 10.1161/JAHA.121.023990
   PubMed Web of Science ®Google Scholar
• Johnson LSB, Juhlin T, Engström G, et al. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace. 2014;16(2):182–188. doi: 10.1093/europace/eut255
   PubMed Web of Science ®Google Scholar
• Noubiap JJ, Tu SJ, Emami M, et al. Incident atrial fibrillation in relation to ventilatory parameters: a prospective cohort study. Can J Cardiol. 2023;39(5):614–622. doi: 10.1016/j.cjca.2023.02.004
   PubMed Web of Science ®Google Scholar
• Cuttica MJ, Colangelo LA, Shah SJ, et al. Loss of lung health from young adulthood and cardiac phenotypes in middle age. Am J Respir Crit Care Med. 2015;192(1):76–85. doi: 10.1164/rccm.201501-0116OC
   PubMed Web of Science ®Google Scholar
• Verbrugge FH, Guazzi M, Testani JM, et al. Altered hemodynamics and End-Organ Damage in Heart failure: impact on the lung and kidney. Circulation. 2020;142(10):998–1012. doi: 10.1161/CIRCULATIONAHA.119.045409
   PubMed Web of Science ®Google Scholar
• Guazzi M, Wilhelm M, Halle M, et al. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - a clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Heart Fail. 2022;24(8):1327–1345. doi: 10.1002/ejhf.2601
   PubMed Web of Science ®Google Scholar
• van der Velden RMJ, Hereijgers MJM, Arman N, et al. Implementation of a screening and management pathway for chronic obstructive pulmonary disease in patients with atrial fibrillation. Europace. 2023;25(7). doi: 10.1093/europace/euad193
   Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi: 10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35–48. doi: 10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi: 10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi: 10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Singh N, Dorfmüller P, Shlobin OA, et al. Group 3 pulmonary hypertension: from bench to bedside. Circ Res. 2022;130(9):1404–1422. doi: 10.1161/CIRCRESAHA.121.319970
   PubMed Web of Science ®Google Scholar
• Goudie AR, Lipworth BJ, Hopkinson PJ, et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2014;2(4):293–300. doi: 10.1016/S2213-2600(14)70013-X
   PubMed Web of Science ®Google Scholar
• Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913–921. doi: 10.1056/NEJMoa1203830
   PubMed Web of Science ®Google Scholar
• Aldabayan YS, Ridsdale HA, Alrajeh AM, et al. Pulmonary rehabilitation, physical activity and aortic stiffness in COPD. Respir Res. 2019;20(1):166. doi: 10.1186/s12931-019-1135-6
   PubMed Web of Science ®Google Scholar
• Vanfleteren LEGW, Spruit MA, Groenen MTJ, et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J. 2014;43(5):1306–1315. doi: 10.1183/09031936.00169313
   PubMed Web of Science ®Google Scholar
• Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on Mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10(6):e019636. doi: 10.1161/JAHA.120.019636
   PubMed Web of Science ®Google Scholar
• Alter P, Mayerhofer BA, Kahnert K, et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2019;14:2163–2172. doi:10.2147/COPD.S209343.
   PubMed Web of Science ®Google Scholar
• Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373–1378. doi: 10.1111/j.1742-1241.2008.01731.x
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med. 2019;381(24):2304–2314. doi: 10.1056/NEJMoa1908142
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210. doi: 10.1056/NEJMoa1403086
   PubMed Web of Science ®Google Scholar
• Pradhan R, Lu S, Yin H, et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ. 2022;379:e071380. doi: 10.1136/bmj-2022-071380
   PubMedGoogle Scholar
• Mancini GBJ, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560. doi: 10.1016/j.jacc.2006.04.039
   PubMed Web of Science ®Google Scholar
• Fawzy A, Putcha N, Aaron CP, et al. Aspirin use and respiratory morbidity in COPD: a propensity score-matched analysis in subpopulations and intermediate outcome measures in COPD study. Chest. 2019;155(3):519–527. doi: 10.1016/j.chest.2018.11.028
   PubMed Web of Science ®Google Scholar
• Kunadian V, Wilson N, Stocken DD, et al. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. ERJ Open Res. 2019;5(3):00110–2019. doi: 10.1183/23120541.00110-2019
   PubMedGoogle Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi: 10.1164/rccm.201711-2239OC
   PubMed Web of Science ®Google Scholar
• Reilev M, Pottegård A, Lykkegaard J, et al. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD. Respirology. 2019;24(12):1183–1190. doi: 10.1111/resp.13620
   PubMed Web of Science ®Google Scholar
• Nordon C, Rhodes K, Quint JK, et al. Exacerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies. BMJ Open. 2023;13(4):e070022. doi: 10.1136/bmjopen-2022-070022
   PubMed Web of Science ®Google Scholar
• Vogelmeier C Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Poster PA3013. Published online 2023.
   Google Scholar
• Wells JM, Criner GJ, Halpin DMG, et al. Mortality risk and serious cardiopulmonary events in moderate-to-severe COPD: Post Hoc analysis of the IMPACT trial. Chronic Obstr Pulm Dis. 2023;10(1):33–45. doi: 10.15326/jcopdf.2022.0332
   PubMed Web of Science ®Google Scholar
• Papi A. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(3):245–251. doi: 10.1513/pats.200512-125SF
   PubMedGoogle Scholar
• Musher DM, Abers MS, Corrales-Medina VF, et al. Acute Infection and Myocardial Infarction. N Engl J Med. 2019;380(2):171–176. doi: 10.1056/NEJMra1808137
   PubMed Web of Science ®Google Scholar
• Skaarup KG, Modin D, Nielsen L, et al. Influenza and cardiovascular disease pathophysiology: strings attached. Eur Heart J Suppl. 2023;25(Suppl A):A5–A11. doi: 10.1093/eurheartjsupp/suac117
   PubMedGoogle Scholar
• Polosa R, Malerba M, Cacciola RR, et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med. 2013;8(7):567–574. doi: 10.1007/s11739-011-0636-1
   PubMed Web of Science ®Google Scholar
• van der Vorm LN, Li L, Huskens D, et al. Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. Respir med. 2020;171:106094. doi: 10.1016/j.rmed.2020.106094
   PubMed Web of Science ®Google Scholar
• Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42(7):1149–1160. doi: 10.1016/s0735-1097(03)00994-x
   PubMed Web of Science ®Google Scholar
• O’Donnell DE. COPD exacerbations. 3: Pathophysiology. Thorax. 2006;61(4):354–361. doi: 10.1136/thx.2005.041830
   PubMed Web of Science ®Google Scholar
• Verhoeff K, Mitchell JR. Cardiopulmonary physiology: why the heart and lungs are inextricably linked. Adv Physiol Educ. 2017;41(3):348–353. doi: 10.1152/advan.00190.2016
   PubMed Web of Science ®Google Scholar
• Cheyne WS, Williams AM, Harper MI, et al. Heart-lung interaction in a model of COPD: importance of lung volume and direct ventricular interaction. Am J Physiol Heart Circ Physiol. 2016;311(6):H1367–H1374. doi: 10.1152/ajpheart.00458.2016
   PubMed Web of Science ®Google Scholar
• Spiesshoefer J, Regmi B, Ottaviani MM, et al. Sympathetic and vagal nerve activity in COPD: pathophysiology, presumed determinants and underappreciated therapeutic potential. Front Physiol. 2022;13:919422. doi: 10.3389/fphys.2022.919422
   PubMed Web of Science ®Google Scholar
• Viglino D, Maltais F, Tamisier R. Common pathophysiological pathways of the autonomic nervous system. In: Cardiovascular Complications of Respiratory DisordersVol. 2020. European Respiratory Society; p. 12–30. 10.1183/2312508X.10027119
   Google Scholar
• Elhage S, Laurent L, Diallo K, et al. Effects of long-acting bronchodilators on cardiac autonomic control in COPD. Respir Med Res. 2022;82:100968. doi: 10.1016/j.resmer.2022.100968
   PubMedGoogle Scholar
• Ferguson GT, Skärby T, Nordenmark LH, et al. Unreported and overlooked: a post hoc analysis of COPD symptom-related attacks from the RISE study. Int J Chron Obstruct Pulmon Dis. 2020;15:3123–3134. doi:10.2147/COPD.S277147.
   PubMed Web of Science ®Google Scholar
• Stevenson IH, Roberts-Thomson KC, Kistler PM, et al. Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm. 2010;7(9):1263–1270. doi: 10.1016/j.hrthm.2010.03.020
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264–274. doi: 10.1001/jama.2014.18229
   PubMed Web of Science ®Google Scholar
• Chang C, Guo Z, Shen N, et al. Dynamics of inflammation resolution and symptom recovery during AECOPD treatment. Sci Rep. 2014;4(1):5516. doi: 10.1038/srep05516
   PubMedGoogle Scholar
• Kyriakopoulos C, Gogali A, Kostikas K, et al. Hypercoagulable State in COPD-A Comprehensive Literature Review. Diagn (Basel). 2021;11(8):1447. doi: 10.3390/diagnostics11081447
   PubMedGoogle Scholar
• Wageck B, Cox NS, Holland AE. Recovery Following Acute Exacerbations of Chronic Obstructive Pulmonary Disease - a Review. COPD: J Chronic Obstructive Pulmonary Dis. 2019;16(1):93–103. doi: 10.1080/15412555.2019.1598965
   PubMed Web of Science ®Google Scholar
• Patel ARC, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091–1099. doi: 10.1164/rccm.201306-1170OC
   PubMed Web of Science ®Google Scholar
• Khedoe PPSJ, Rensen PCN, Berbée JFP, et al. Murine models of cardiovascular comorbidity in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2016;310(11):L1011–27. doi: 10.1152/ajplung.00013.2016
   PubMed Web of Science ®Google Scholar
• Gabriel CL, Ferguson JF. Gut microbiota and microbial metabolism in early risk of cardiometabolic disease. Circ Res. 2023;132(12):1674–1691. doi: 10.1161/CIRCRESAHA.123.322055
   PubMed Web of Science ®Google Scholar
• Lagan J, Schelbert EB, Naish JH, et al. Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease with Heart Failure. JACC Cardiovasc Imaging. 2021;14(10):1963–1973. doi: 10.1016/j.jcmg.2021.03.026
   PubMed Web of Science ®Google Scholar
• Hurst JR, Gale CP, Global Working Group on Cardiopulmonary Risk. MACE in COPD: addressing cardiopulmonary risk. Lancet Respir Med. 2024 Mar 1. 10.1016/S2213-2600(24)00038-9
   Google Scholar